Fed Circuit affirms generic maker’s win over Eagle
11-05-2020
Igorgolovniov / Shutterstock.com
London-based Hikma Pharmaceuticals has won approval to launch the first generic version of Vascepa (icosapent ethyl), after having key Amarin patents for the heart drug invalidated.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
FDA, Hikma, Amarin, Vascepa, Dr Reddy’s, ANDA, generics, Securities Exchange Commission, COVID-19
